TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2938194

Group type: EXPERIMENTAL
Intervention: 0.5 mg ipratropium combined with 1.25 mg, 2.5 mg or 5.0 mg fenoterol
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5.0 mg salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined preparations (ipratropium and fenoterol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 10
Study: 28884881

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for weight loss
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combined intervention groups
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 91
Study: 27689549

Group type: EXPERIMENTAL
Intervention: Simultaneous stimulation via cathodal tDCS over the cM1 combined with 10 Hz rTMS over the iM1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Other treatment conditions
Number of subjects: 20
Study: 23686640

Group type: EXPERIMENTAL
Intervention: GSD (oral glucose spray) - 10 puffs delivering 50 mg of glucose per puff
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no GSD)
Number of subjects: 56
Study: 22561965

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 20440028

Group type: EXPERIMENTAL
Intervention: Accelerometers (ACC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ACC cut‐point ranges
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ACC estimates of absolute PAI
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ACC output expressed in relative vs. absolute terms
Number of subjects: 90
Study: 19099974

Group type: EXPERIMENTAL
Intervention: Unstable Angina (UA) group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acute Myocardial Infarction (AMI) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stable Angina (SA) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chest Pain Control (CPS) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal Control group
Number of subjects: 60
Study: 16463697

Group type: EXPERIMENTAL
Intervention: Incremental cycling exercise test performed after blood donation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Incremental cycling exercise test performed before blood donation (control study)
Number of subjects: 13
Study: 12185425

Group type: EXPERIMENTAL
Intervention: 30-min spontaneous breathing trial (SBT) with pressure support ventilation (PSV) at 7 cmH(2)O
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 120-min spontaneous breathing trial (SBT) with pressure support ventilation (PSV) at 7 cmH(2)O
Number of subjects: 98

Group type: COMPARATOR
Intervention: Comparison of reintubated patients
Number of subjects: 98

Group type: COMPARATOR
Intervention: ICU mortality
Number of subjects: 98

Group type: COMPARATOR
Intervention: In-hospital mortality
Number of subjects: 98

Group type: COMPARATOR
Intervention: Length of ICU stay
Number of subjects: 98

Group type: COMPARATOR
Intervention: In-hospital length of stay
Number of subjects: 98
Study: 10514116

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 154

Group type: COMPARATOR
Intervention: No Endoscopy
Number of subjects: 154
Study: 7815582

Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound following papaverine stimulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Color duplex ultrasound
Number of subjects: 22
Study: 2020763

Group type: EXPERIMENTAL
Intervention: Nimorazole (NIM)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study: 6757940

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham plasma exchange
Number of subjects: 14
Study: 30007557

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1765

Group type: EXPERIMENTAL
Intervention: Post-randomization AF
Number of subjects: 1765

Group type: COMPARATOR
Intervention: No known AF / History of AF without AF at enrollment / AF found on ECG at enrollment
Number of subjects: 1765
Study: 26981935

Group type: EXPERIMENTAL
Intervention: Complex intervention comprising professional education, informatics, and financial incentives for practices to review patients' charts.
Number of subjects: 33334
Study: 24549255

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa extract (HSE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 21350049

Group type: EXPERIMENTAL
Intervention: Somatosensory discrimination training (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Repeated exposure to sensory stimuli (n = 25)
Number of subjects: 50
Study: 18762972

Group type: EXPERIMENTAL
Intervention: Cognitive distractor (verbal judgment of target distance)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Motor distractor (additional movement with right or left hand)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 44
Study: 17944738

Group type: EXPERIMENTAL
Intervention: Low-volume 5-aminosalicylic acid foam (2 x 1 g/30 mL)
Number of subjects: 330

Group type: COMPARATOR
Intervention: High-volume 5-aminosalicylic acid foam (2 x 1 g/60 mL)
Number of subjects: 330
Study: 15488868

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atherogenic dyslipoproteinemia (ADL) subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 0
Study: 11549328

Group type: EXPERIMENTAL
Intervention: Identity exploration activities
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Commitment to avoiding roles
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Emerging self-definitions for highly desired possible selves
Number of subjects: 76
Study: 9884941

Group type: EXPERIMENTAL
Intervention: Modified preparation (13.9‐17.6 GBq 99mTcO4‐)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Regular preparation (4.4‐8.8 GBq 99mTcO4‐)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MRPC for QC testing
Number of subjects: 58

Group type: COMPARATOR
Intervention: ITLC/SG for QC testing
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 58
Study: 7532938

Group type: EXPERIMENTAL
Intervention: Tranilast and local treatment (nasal and tubal)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Local treatment (control for Group A)
Number of subjects: 62
Study: 3061819

Group type: EXPERIMENTAL
Intervention: 2 mg of perindopril once daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 mg of perindopril once daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 8 mg of perindopril once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30088288

Group type: EXPERIMENTAL
Intervention: WL + RT
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: WL
Number of subjects: 187

Group type: COMPARATOR
Intervention: WL + AT
Number of subjects: 187
Study: 26073355

Group type: EXPERIMENTAL
Intervention: 40 mg Rosuvastatin tablet formulation 1
Number of subjects: 24

Group type: COMPARATOR
Intervention: 40 mg Rosuvastatin tablet formulation 2
Number of subjects: 24
Study: 25661510

Group type: EXPERIMENTAL
Intervention: LNG‐IUS 13.5mg
Number of subjects: 1432
Study: 23060530

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 21040130

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrodesiccation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 10
Study: 18082788

Group type: EXPERIMENTAL
Intervention: Mechanical reperfusion using primary percutaneous coronary intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment with fibrinolytics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive therapies including beta-blockers, aspirin (or clopidogrel if aspirin is contraindicated), nitroglycerin, and analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel as adjunctive therapy for patients undergoing fibrinolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin and low-molecular-weight heparin as adjunctives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple new antithrombin agents
Number of subjects: 0
Study: 16412156

Group type: EXPERIMENTAL
Intervention: Web-based computer program used before doctor visit
Number of subjects: 53
Study: 12817175

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg (DBPC trials)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg (PROBE trials)
Number of subjects: 860
Study: 10877480

Group type: EXPERIMENTAL
Intervention: Supplementary rest break schedule (includes two 15-min breaks and an additional 5-min break each hour)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional rest break schedule (includes two 15-min breaks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Supplementary rest break schedule
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both schedules
Number of subjects: 42
Study: 9105068

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice a day
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg twice a day
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 8252318

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naproxen 1500 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naproxen combined with 4 g paracetamol daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lower naproxen doses with paracetamol
Number of subjects: 20
Study: 3515924

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Zomepirac sodium 100 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine 650 mg + 60 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 31351444

Group type: EXPERIMENTAL
Intervention: Care manager function in collaborative care
Number of subjects: 40
Study: 29116880

Group type: EXPERIMENTAL
Intervention: C. difficile vaccine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 26208120

Group type: COMPARATOR
Intervention: Group cognitive remediation (CR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Individual cognitive remediation (CR)
Number of subjects: 25
Study: 21911650

Group type: EXPERIMENTAL
Intervention: Subretinal gene therapy using recombinant adeno‐associated virus 2 (rAAV2) carrying the RPE65 gene
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subretinal gene therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 15
Study: 20089951

Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg orally twice daily)
Number of subjects: 3408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3408

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 3408
Study: 17884802

Group type: EXPERIMENTAL
Intervention: Mandibular nerve block (MNB) with ropivacaine 10 mg ml(‐1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (normal saline injection)
Number of subjects: 42
Study: 15122134

Group type: EXPERIMENTAL
Intervention: Arthroscopic repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 12202471

Group type: EXPERIMENTAL
Intervention: Hydroxylated vitamin D
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Standard vitamin D
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vitamin D (both standard and hydroxylated)
Number of subjects: 25
Study: 9661575

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg preoperatively and 8 mg.kg‐1.h‐1 intraoperatively
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution
Number of subjects: 46
Study: 8697927

Group type: EXPERIMENTAL
Intervention: Lansoprazole (L)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Omeprazole (O)
Number of subjects: 72
Study: 2792672

Group type: EXPERIMENTAL
Intervention: Garren‐Edwards gastric bubble (GEGB)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham insertion
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both groups (GEGB and sham)
Number of subjects: 59
Study: 14659

Group type: EXPERIMENTAL
Intervention: medazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: chlordiazepoxide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: amylobarbitone
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 29956034

Group type: EXPERIMENTAL
Intervention: Individual therapy (Habit reversal training and exposure response prevention)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Group therapy (Habit reversal training and exposure response prevention)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both therapies (Individual and Group)
Number of subjects: 59
Study: 27716668

Group type: EXPERIMENTAL
Intervention: Potentially Inappropriate Medications (PIM) identified using the Priscus list
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: PIM prescription rates
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Diagnosis of a mental or behavioral disorder
Number of subjects: 448
Study: 26947279

Group type: EXPERIMENTAL
Intervention: PCV7-TT
Number of subjects: 40

Group type: COMPARATOR
Intervention: PNEUMO-23
Number of subjects: 40
Study: 23057654

Group type: EXPERIMENTAL
Intervention: Tai chi (TC) for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aerobic exercise for 12 weeks
Number of subjects: 16
Study: 20505749

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 1320
Study: 19639690

Group type: EXPERIMENTAL
Intervention: Intranasal electrophoresis using mexidol
Number of subjects: 0
Study: 17910224

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide gel
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 30% carbamide peroxide gel
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 13
Study: 15851743

Group type: EXPERIMENTAL
Intervention: Nighttime pergolide (1 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11805862

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (3 x 30 min of stationary cycling at 70% of peak aerobic power for 9 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serotonin agonist (buspirone hydrochloride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10363422

Group type: EXPERIMENTAL
Intervention: AZT and ddl
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AZT
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 8750367

Group type: EXPERIMENTAL
Intervention: High-dose aerosolized pentamidine prophylaxis (300 mg twice a month or 600 mg once a month)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard-dose aerosolized pentamidine prophylaxis (300 mg once a month)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High-dose aerosolized pentamidine prophylaxis (300 mg twice a month)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High-dose aerosolized pentamidine prophylaxis (600 mg once a month)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High-dose aerosolized pentamidine prophylaxis
Number of subjects: 180
Study: 2150073

Group type: EXPERIMENTAL
Intervention: Light-cured glass ionomer liner (Espe, Seefeld/Oberbay, FRG)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Auto-cured glass ionomer cements (Vitrabond and another unspecified auto-cured cement)
Number of subjects: 99
Study: 6995186

Group type: EXPERIMENTAL
Intervention: 500 mg griseofulvin-FP daily for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31950977

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 26828

Group type: COMPARATOR
Intervention: Histamine-2 Receptor Blockers (H2RBs)
Number of subjects: 26828
Study: 31003878

Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced peripheral neuropathy (CIPN) assessment and management communication
Number of subjects: 159
Study: 26990171

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 μg BID
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study: 22934930

Group type: EXPERIMENTAL
Intervention: NAL prescription for hearing aids
Number of subjects: 218

Group type: COMPARATOR
Intervention: DSL prescription for hearing aids
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Parents' ratings of children's device usage
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Parents' ratings of loudness discomfort
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Functional performance within the first year of fitting
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Additional disabilities and maternal education
Number of subjects: 218
Study: 21473823

Group type: EXPERIMENTAL
Intervention: Single hole exhalation valve
Number of subjects: 47

Group type: COMPARATOR
Intervention: Plateau exhalation valve
Number of subjects: 47
Study: 19969160

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided injection of 20 mg triamcinolone mixed with 1.5 mL 2% lidocaine and 4 mL normal saline followed by 5 weekly injections of sodium hyaluronate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Blind injection of 20 mg triamcinolone mixed with 1.5 mL 2% lidocaine and 4 mL normal saline followed by 5 weekly injections of sodium hyaluronate
Number of subjects: 43
Study: 17675595

Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (LSVT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not receiving LSVT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy individuals (age-matched)
Number of subjects: 14
Study: 14998846

Group type: EXPERIMENTAL
Intervention: PLD 50 mg/m2 (every 4 weeks)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m2 (every 3 weeks)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: PLD
Number of subjects: 509
Study: 11685057

Group type: EXPERIMENTAL
Intervention: Dry Eye Test (DET) modified fluorescein strip
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard fluorescein strip (FUL-GLO)
Number of subjects: 75
Study: 9532992

Group type: EXPERIMENTAL
Intervention: Transcervical amnioinfusion of 500 mL saline over 30 minutes, then 500 mL at 30 drops per minute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 8018112

Group type: EXPERIMENTAL
Intervention: elaidic acid-rich diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: oleic acid diet
Number of subjects: 27
Study: 2684660

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg kg‐1 i.v. followed by a ketamine infusion of 2 mg kg‐1 h‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 30
Study: 1031487

Group type: EXPERIMENTAL
Intervention: Physical training starting in the 10th or 14th week of pregnancy until term
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 62
Study: 31932495

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 289
Study: 30144380

Group type: EXPERIMENTAL
Intervention: GlucoTab (GT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 10
Study: 28070862

Group type: EXPERIMENTAL
Intervention: CAM2038 q4w 96 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CAM2038 q4w 192 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sublingual buprenorphine 8, 16, or 24 mg daily for 7 days
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CAM2038 q1w 16 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CAM2038 q1w and q4w
Number of subjects: 87
Study: 25706589

Group type: EXPERIMENTAL
Intervention: Teacher professional development program (workshops and in-classroom coaching)
Number of subjects: 1876
Study: 24616989

Group type: EXPERIMENTAL
Intervention: Older age-group (age >= 60)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Senile sudden deafness patients (disease time <= 7 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Senile sudden deafness patients (disease time > 7 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Total effective rate of senile sudden deafness patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Senile sudden deafness patients with moderate deafness (hearing threshold < 55 dB)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (younger patients) with moderate deafness (hearing threshold < 55 dB)
Number of subjects: 140
Study: 21638187

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (control)
Number of subjects: 25
Study: 19465880

Group type: EXPERIMENTAL
Intervention: Fluoxetine alone (n = 109)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy alone (n = 111)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Combination treatment (n = 107)
Number of subjects: 327
Study: 16959450

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine (EMLA patch 5%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no lidocaine-prilocaine)
Number of subjects: 24
Study: 15465753

Group type: EXPERIMENTAL
Intervention: Multimicronutrient interventions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Iron interventions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vitamin A interventions
Number of subjects: 40